Year | Reference | Country | Age (years) | Sample size | IgAD (prevalence) | Criteria (g/L) |
---|---|---|---|---|---|---|
1992 | 113 | Sweden | 20–68 | 24 | 4 (1:6) | NM |
1997 | 117 | Italy | 0–15 | 688 | 12 (1:58) | <0.05 |
1997 | 114 | Ireland | NM | 604 | 14 (1:43) | <0.05 |
1998 | 115 | Italy | 0–15 | 1,776 | 46 (1:39) | <0.05 |
 |  |  | 18–65 | 322 | 8 (1:40) | <0.05 |
2000 | 116 | Turkey | 0–16 | 104 | 3 (1:35) | NM |
2000 | 223 | Spain | NM | 47 | 5 (1:10) | <0.07 |
Total | Â | Â | Â | 3,565 | 92 (1:39) | Â |
2006 | 124 | UK | NM | 4,698a | 35 (1:131) | <0.06 |
2008 | 118 | Canada | NM | 608a | 4 (1:152) | <0.05 |
Present study | Â | Sweden | Children, adults | 422,225a | 2,309 (1:192) | <0.07 |
Total | Â | Â | Â | 427,531 | 2,348 (1:182) | Â |